Schalekamp MA - Search Results

1

Contrasting response to cyclosporin in refractory nephrotic syndrome.

Zietse R, Wenting GJ, Kramer P, Mulder P, Schalekamp MA, Weimar W. Zietse R, et al. Among authors: schalekamp ma. Clin Nephrol. 1989 Jan;31(1):22-5. Clin Nephrol. 1989. PMID: 2914407

2

Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.

Zietse R, Wenting GJ, Kramer P, Schalekamp MA, Weimar W. Zietse R, et al. Among authors: schalekamp ma. Clin Sci (Lond). 1992 Jun;82(6):641-50. doi: 10.1042/cs0820641. Clin Sci (Lond). 1992. PMID: 1320544

3

Effect of synthetic human atrial natriuretic peptide (102-126) in nephrotic syndrome.

Zietse R, Schalekamp MA. Zietse R, et al. Among authors: schalekamp ma. Kidney Int. 1988 Nov;34(5):717-24. doi: 10.1038/ki.1988.238. Kidney Int. 1988. PMID: 2974095 Free article. Clinical Trial.

4

Fractional excretion of protein: a marker of the efficacy of cyclosporine A treatment in nephrotic syndrome.

Zietse R, Wenting GJ, Kramer P, Schalekamp MA, Weimar W. Zietse R, et al. Among authors: schalekamp ma. Transplant Proc. 1988 Jun;20(3 Suppl 4):280-4. Transplant Proc. 1988. PMID: 3381284 No abstract available.

5

Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus.

Zietse R, Derkx FH, Weimar W, Schalekamp MA. Zietse R, et al. Among authors: schalekamp ma. J Am Soc Nephrol. 1995 Jun;5(12):2057-66. doi: 10.1681/ASN.V5122057. J Am Soc Nephrol. 1995. PMID: 7579054 Clinical Trial.

6

Cyclosporin and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy.

Zietse R, Derkx FH, Schalekamp MA, Weimar W. Zietse R, et al. Among authors: schalekamp ma. Contrib Nephrol. 1995;114:6-18. doi: 10.1159/000424280. Contrib Nephrol. 1995. PMID: 7587200 No abstract available.

7

Optimising glomerular filtration rate and effective renal plasma flow measurements using a simple pharmacokinetic model.

Zietse R, Blankestijn PJ, Pos B, Balk AH, Derkx FH, Weimar W, Schalekamp MA. Zietse R, et al. Among authors: schalekamp ma. Clin Nephrol. 1995 Jan;43(1):29-34. Clin Nephrol. 1995. PMID: 7697933

8

Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon.

Brouwer RM, Wenting GJ, Schalekamp MA. Brouwer RM, et al. Among authors: schalekamp ma. J Cardiovasc Pharmacol. 1990 Jun;15(6):868-76. doi: 10.1097/00005344-199006000-00003. J Cardiovasc Pharmacol. 1990. PMID: 1694908

9

Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.

van den Meiracker AH, Admiraal PJ, Man in 't Veld AJ, Derkx FH, Ritsema van Eck HJ, Mulder P, van Brummelen P, Schalekamp MA. van den Meiracker AH, et al. Among authors: schalekamp ma. BMJ. 1990 Jul 28;301(6745):205-10. doi: 10.1136/bmj.301.6745.205. BMJ. 1990. PMID: 2203486 Free PMC article. Clinical Trial.

10

The clinical pharmacology of bopindolol, a new long-acting beta-adrenoceptor antagonist, in hypertension.

van den Meiracker AH, Man in 't Veld AJ, van Eck HJ, Boomsma F, Derkx FH, Mulder P, Schalekamp MA. van den Meiracker AH, et al. Among authors: schalekamp ma. Clin Pharmacol Ther. 1987 Oct;42(4):411-9. doi: 10.1038/clpt.1987.171. Clin Pharmacol Ther. 1987. PMID: 2889554 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

332 results

Search Page

Filters